Scarica l'app Stockscreener
8.50
1.43%
0.12
Dopo l'orario di chiusura:
8.86
0.36
+4.24%
Precedente Chiudi:
$8.38
Aprire:
$8.3
Volume 24 ore:
27,014
Relative Volume:
0.58
Capitalizzazione di mercato:
$55.93M
Reddito:
-
Utile/perdita netta:
$-31.48M
Rapporto P/E:
-8.1731
EPS:
-1.04
Flusso di cassa netto:
$-28.71M
1 W Prestazione:
+0.12%
1M Prestazione:
+16.44%
6M Prestazione:
-60.85%
1 anno Prestazione:
-45.60%
Intervallo 1D:
$8.28
$8.99
Intervallo di 1 settimana:
$8.25
$13.84
Portata 52W:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Nome
Forte Biosciences Inc
Settore
Industria
Telefono
(310) 618-6994
Indirizzo
3060 PEGASUS PARK DRIVE, DALLAS, CA
Confronta FBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
8.50 | 55.89M | 0 | -31.48M | -28.71M | -1.04 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-21 | Iniziato | TD Cowen | Buy |
| 2024-04-08 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | Aggiornamento | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | Downgrade | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | Downgrade | Truist | Buy → Hold |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-03-26 | Iniziato | Citigroup | Buy |
| 2020-08-28 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | Iniziato | Truist | Buy |
Mostra tutto
Forte Biosciences Inc Borsa (FBRX) Ultime notizie
Forte Biosciences reports annual meeting results - Investing.com
Forte Biosciences Elects New Directors at Annual Meeting - TipRanks
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
How the (FBRX) price action is used to our Advantage - news.stocktradersdaily.com
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews
Top Premarket Decliners - marketscreener.com
Forte Biosciences Reports Increased Losses Amid R&D Expansion - TipRanks
Forte Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Forte Biosciences Q1 Operating Expenses USD 16.124 Million - marketscreener.com
Forte Biosciences (FBRX) Advances Trials for FB102 in Celiac Disease and Vitiligo | FBRX Stock News - GuruFocus
Forte Biosciences reports Q1 EPS ($1.37), consensus (95c) - TipRanks
Forte Biosciences, Inc. Announces Results and Provides Update - Eagle-Tribune
Forte Biosciences Q1: Celiac Disease Trial Results Imminent, New Vitiligo Study Launches - Stock Titan
Stock Traders Buy High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
Forte Biosciences (FBRX) Expected to Announce Earnings on Monday - Defense World
JPMorgan Chase & Co. Trims Stock Holdings in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Royal Bank of Canada Has Lowered Expectations for Zimmer Biomet (NYSE:ZBH) Stock Price - Defense World
JPMorgan Chase & Co. Buys New Holdings in Innovator U.S. Equity Accelerated ETF – January (BATS:XDJA) - Defense World
(FBRX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Stock Position in AmpliTech Group, Inc. (NASDAQ:AMPG) - Defense World
Geode Capital Management LLC Increases Position in Forte Biosciences, Inc. (NASDAQ:FBRX) - Defense World
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Meta Doubles Down on AI: Is the Stock Ready to Skyrocket? - The Globe and Mail
Shining a Light on IL-13: Optimizing Moderate-to-Severe Atopic Dermatitis Treatment in Daily Practice - Healio
Forte Biosciences sets Annual Meeting for May 29 By Investing.com - Investing.com Canada
Forte Biosciences sets Annual Meeting for May 29 - Investing.com Australia
Traders Buy High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
Mr. Ethan Billings recommends paying close attention to biotech stocks - FinancialContent
Profit from Trump’s Tariff Playbook with TipRanks’ New Comparison Tool - The Globe and Mail
Nvidia and Broadcom Helped Propel This ETF 18% Higher in a Single Day. Here's Why It's Still a Buy Now. - The Globe and Mail
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Analysts Issue Forecasts for FBRX Q2 Earnings - Defense World
Equities Analysts Offer Predictions for FBRX FY2025 Earnings - Defense World
(FBRX) Investment Analysis - news.stocktradersdaily.com
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy - MSN
Forte Biosciences (NASDAQ:FBRX) Given New $61.00 Price Target at Chardan Capital - The AM Reporter
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Chardan Capital Issues Pessimistic Forecast for Forte Biosciences (NASDAQ:FBRX) Stock Price - Defense World
Chardan Adjusts Price Target on Forte Biosciences to $61 From $64, Maintains Buy Rating - MarketScreener
Forte Biosciences Reports 2024 Progress and Financials - TipRanks
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans? - Yahoo
Forte's Celiac Treatment Shows Promise: Zero Dropouts and $58.4M War Chest - Stock Titan
Forte Biosciences, Inc. Announces Results and Provides Clinical Update - Bluefield Daily Telegraph
Forte Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Forte Biosciences Inc Files For Mixed Shelf Of Up To $300 MillionSEC Filing - MarketScreener
Forte Biosciences, Inc. SEC 10-K Report - TradingView
Forte Biosciences Inc. (FBRX) reports earnings - Quartz
(FBRX) Long Term Investment Analysis - news.stocktradersdaily.com
Forte Biosciences Inc Azioni (FBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):